Aakaar Medical Technologies Share Price Today

Aakaar Medical Technologies approves ESOP Scheme at 13th AGM

Aakaar Medical Technologies Limited held its 13th Annual General Meeting on June 30, 2026, approving the ESOP 2026 Scheme and increasing authorised share capital to ₹15.40 crore. Shareholders re-appointed Mr. Dilip Meswani as Director and appointed a secretarial auditor for five years starting FY2026-27. The auditors reported no qualifications for FY2025-26.

Aakaar Medical Technologies revenue rises to ₹66.9 crore in FY26

Aakaar Medical Technologies Limited reported revenue of ₹66.9 crore for FY26, up from ₹61.6 crore in FY25. PAT increased to ₹6.6 crore, and EBITDA stood at ₹10.97 crore with a margin of 16.39%. The company's balance sheet expanded to ₹79.4 crore, driven by growth in shareholders' funds and cash reserves.

Aakaar Medical Technologies sets June 30 for 13th AGM

Aakaar Medical Technologies Limited will conduct its 13th AGM on June 30, 2026, via video conference. The company has dispatched the annual report for FY26 and opened remote e-voting from June 29, 2026, with a cut-off date of June 23, 2026, for shareholder eligibility.

Aakaar Medical FY26 PAT rises 10% to ₹6.63 crore

Aakaar Medical Technologies Limited reported a 10% increase in Profit After Tax (PAT) to ₹6.63 crore for the financial year ended March 31, 2026, on revenue of ₹66.96 crore. The Board has proposed an Employee Stock Option Plan (ESOP) for up to 11,33,825 options and an increase in authorised share capital to ₹15.40 crore, subject to shareholder approval at the AGM on June 30, 2026.

Aakaar Medical FY26 PAT rises to ₹663.76 lakh

Aakaar Medical Technologies Limited announced its audited financial results for the year ended March 31, 2026, reporting a net profit of ₹663.76 lakh, up from ₹603.20 lakh in the previous year. Revenue from operations increased to ₹6,696.41 lakh from ₹6,158.28 lakh in FY25. The Board of Directors approved the results and the re-appointment of Mr. Dilip Ramesh Meswani as Non-Independent Director, subject to shareholder and SEBI approval. Statutory auditors M/s. C.B. Mehta & Associates issued an unmodified opinion on the financial statements.

Aakaar Medical approves ESOP 2026, hikes share capital

Aakaar Medical Technologies Limited approved the Aakar Medical Technologies Employee Stock Option Plan 2026 for 11.33 lakh options and increased authorized share capital to ₹15.40 crore. The options are exercisable into equity shares of ₹10 each, with a vesting period of at least 12 months. Both approvals are subject to shareholder consent.